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In Chapter 175, a detailed history of organ transplantation is 
provided. In order to foster the appreciation and understand-
ing of the forces that will drive advances in transplantation 
into the next century, this chapter focuses on a few of the 
past developments in transplantation that have helped to 
shape current transplant practices (Fig. 185-1). The beginning 
of solid-organ transplantation can be traced back to the techni-
cal achievement of Alexis CarreP; in 1902, he described the 
techniques of vascular anastomosis, thus ushering in accounts 
of autologous and homologous transplantation. Although a 
number of animal-ta-human kidney transplants were reported 
in the ensuing three decades, a human donor organ was not 
used until 1933, by the Russian surgeon Voronoy.2 This and 
other attempts at using human kidneys for transplantation 
failed owing to acute tubular necrosis and rejection. The first 
successful human transplant was performed on December 23, 
1954, by the Boston team of Moore, Murray, Merrill, and 
Harrison.3 The transplantation of an identical twin kidney 
from one brother to another was the immunologic advantage 
that distinguished the early successes in kidney transplanta-
tion from those that otherwise were doomed to fail. 
Gibson and Medawar ascribed an immunologic basis to the 
rejection of tissues between genetically nonidentical individu-
als. In 1960, Caine and Murrays used azathioprine, developed 
several years earlier by Burroughs-Wellcome, in attempts to 
gain success in unrelated kidney transplantation using immu-
nosuppressive agents. Starzl and colleagues" then modified 
the immunosuppressive regimen by adding corticosteroids for 
rejection and began routinely to achieve success. This success 
led to growing attempts at human kidney transplantation, 
aggravating the shortage of organs to use for transplantation. 
A number of animal-ta-human transplantations were at-
tempted. The longest survivor was a 23-year-old woman who 
lived for 9 months after receiving kidneys from a chimpanzee.' 
In 1 %8, the Ad Hoc Committee of the Harvard School of 
Medicine proposed the concept of "irreversible coma."8 Fur-
ther clarification of the pathophysiology of irreversible brain 
stem injury and subsequent somatic death followed, as did 
objective criteria to document irreversible brain injury. The 
brain death concept has eventually been accepted throughout 
the United States (see Chapter 174). The details of brain death 
evaluation and certification vary from state to state but require 
a clinical picture of (1) coma not due to drug overdose (e.g., 
alcohol) or to physical reasons (e.g., hypothermia) and (2) 
lack of cranial nerve retlexes. Continnatory tests are used to 
document the absence of blood flow to the brain and the lack 
of cerebral and brain stem electric activity. The use of brain-
dead donors. with optimal hemodynamic parameters, offers 
the possibility of better-quality organs with minimum damage 
from warm ischemia. It has also allowed procurement of 
extrarenal organs in a ~iystematic manner.· Another improve-
ment in the area of donor management was the development 
of preservation solutions. first Collins solution") and currently 
-----_._---------------
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Figure 185-1. Abbreviated chronologie summary of significant milestones in transplantation. 
Viaspan, developed by Belzer and Southard" at the University 
of Wisconsin (see Chapter 178). 
The next advancement in the field of transplantation came 
with the discovery of the immunosuppressive qualities of 
cyclosporine, described by Borel and colleagues. l' Clinical 
trials of this agent were conducted in England by Caine and 
colleagues U and shortly thereafter in the United States by 
Starzl and colleagues." The combination of cyclosporine and 
steroids was soon introduced into clinical transplantation, and 
the impact on liver, heart, and kidney transplantation was felt 
almost overnight. With the introduction of cyclosporine into 
clinical transplantation, survival rates for patients and grafts 
improved dramatically (see Chapter 178). 
Nevertheless, allograft rejection and the consequences of 
the treatment of rejection continue to constitute one of the 
most common causes of retransplantation or death. Clinical 
rejection occurs in as many as 80% of reCipients of solid-organ 
allografts. who are maintained on a cyclosporine and steroid 
regimen. In addition, a number of toxicities, including nephro-
toXicity, may limit the optimal use of cyclosporine. Chronic 
renal damage and functional impairment have been shown to 
occur in transplant recipients, and hypertension requiring 
antihypertensive therapy occurs in the majority of these pa-
tients. Alterations in clinical immunosuppression to prevent 
or reverse these and other side effects have included (1) 
reduction of cyclosporine dose and (2) the addition of azathio-
prine. antilymphocvte antibodies, or other agents, with con-
comitant reductions in the cyclosporine dose. These meth-
odols have their inherent dangers. increasing susceptibility to 
both rejection and infection. 
Organ transplantation is now accepted as a therapeutic 
modality ti>r treatment of various end-stage organ diseases. 
The cost of kidney transplantation has been paid bv Medicare 
and the End-Stage Renal Disease Program tor more than 1') 
Years. The costs of liver, heart, and heart-lung transplantations 
have been paid by a majority of third-pam' insurances tor 
more than 10 years: Medicare has also recognized the benefits 
of these procedures and has developed entitlement programs 
covering these procedures. Pancreas, lung, and intestinal trans-
plantations have not yet been universally subscribed to by 
third-party payers, but as experience accumulates and the 
efficacy of these procedures is proved, it is likely that these 
procedures will also be covered by Medicare. As experience 
in organ transplantation grows and the experimental proce-
dures also become accepted, the pressure exerted on a limited 
donor pool continues to increase. Donors who have not pre-
viously been used are being considered. and more attention 
is focused on artificial support systems and the area of xeno-
transplantation. 
This chapter attempts to put into perspective some of the 
areas of research and development that may affect the future 
of transplantation. References to other chapters detail the 
developments in those areas that are worth mentioning in 
the context of future developments in the field of organ 
transplantation. It is not possible here to mention all of the 
various fields that may affect the future of transplantation, and 
omission of an area of interest does not in any way suggest 
that such an area is not important. 
UPDATE ON SUCCESSFUL 
SOLlD·ORGAN TRANSPLANTATION 
In 1984. the National Organ Transplant Act (NOTA) was 
passed by the Congress of the United States. TIl is act called 
for formation of an organ procurement network and a scien-
tific registrY (see Chapter 17';). In 1987. the United Network 
of Organ Sharing (UN OS) was awarded a contract by the 
Health Resources and Services Administr.ltion to maintain a 
scientific registry for organ transplantation. One of the pur-
poses of the registry is to collect and analyze data regarding 
the success of organ transplantation and the factors that are 
important in determining success. This registry represents one 
of the first attempts to examine the role of donor and recipi-
ent characteristics. as well as center-specific parameters, that 
-.. _,-------------------------------- ._-------_._-
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affect organ transplantation, The factors analyzed have in-
cluded (1) age and race of the recipient, (2) risk factors in 
the recipient population. and (3) the medical urgency of 
the recipient population. TIlese factors were then applied to 
national and center-specific outcomes. In 1992. the first Re-
port of Center-SpecifiC Graft and Patient Survival Rates was 
published": it was followed by two additional analyses. in 
1994 16 and 1997. 1- The data cited in the following pages have 
been abstracted from published UNOS statistics in the 1997 
Annual Report for the United States experience. I" In all organ 
transplant types, the registry has recorded an improvement in 
patient and graft survival during the period that has been 
analyzed. This improvement is in part related to better medical 
management. greater experience at the individual transplant 
centers, and changing recipient characteristics. 
Kidney 
The current I-year patient survival rate for cadaveric kidney 
transplants is 94.7%, which is slightly lower. at 88%. by 3 
years after transplantation; The 1- and 3-year graft survival 
rates are 86.6% and 72.1%. respectively. A patient whose 
kidney allograft fails can be put back on dialysis support. 
accounting for the significant differences between patient and 
graft survival rates, 
The following factors appear to adversely affect the success 
of cadaveric kidney transplants: 
1. Repeat transplants (-6% worse 3-year graft survival than 
first-time kidney transplant). 
2. Blacks as recipients (-10% worse 3-year graft survival 
rates compared with white recipients: -15% worse 3-year 
graft survival rates compared with Asian reCipients). 
3, Poor histocompatibility (HLA) matching (14% worse 3-
year graft survival rates in the worst match compared with 
the best match). 
·t Very young «5 years of age) or very old (>65 years of 
age) recipients. 
TIle corresponding biologic explanations for these risk fac-
tors are as follows: 
1. Greater likelihood of sensitization of the recipient in 
repeated transplantation. 
2. Worse matching characteristics in the black population 
than in white and Asian populations. 
3. TIle role of histocompatibility. as determined by HLA 
matching, in the intensity of the rejection process. 
-4. Concurrent medical problems in the elderly and greater 
technical complications in the very young. 
Living donors have been used for kidney transplantation 
since the earliest attempts at kidney transplantation. The over-
all gr.Ift and patient survival rates for recipients of living donor 
kidneys are better than for recipients of cadaveric kidney 
tr.Insplants. The 1- and 3·year patient survival rates for living 
donor recipients are 9"7.9% and 94.1 %. respectively: the corre-
sponding 1- and ;-year grill survival rates are 93.;% and 
H'i.2"'1. Man\' of the risk factors that adversely intluence graft 
surviv;11 in cadaveric kidney recipients also apply in living 
donor recipients. -nle biologic explanation for the better graft 
~tnd patient survival r.Ites in the living donor group compared 
with the cadaveric organ recipients is principally related [() 
doser HLA matching and better-qualiry kidney allowafts. with 
impro\'ed earl\' graft function. TIle onset of early acute tubular 
necrosis after kidnev transplantation. from either presen':ltion 
nr immunologic causes. has a deleterious effect on graft sur-
\·ival. 
Liver 
The current 1- and 3-year patient survival rates after liver 
transplantation are 87.0% and 77.4%, respectively; the corre-
sponding graft survival rates are 79.1% and 66.4%. Unlike 
failure of kidney transplantation, failure of a liver graft results 
in a patient's death unless the patient undergoes retransplanta-
tion. 
The risk factors associated with poorer outcomes in liver 
transplantation are as follows: 
1. Older (>65 years of age) recipient age (3-year patient 
survival rate for this group is 8% less than the mean rate). 
2. Repeat transplants (3-year survival rate for recipient of 
previous transplants was 23.5% less than for those receiving 
only one transplant). 
3. Asian race (3-year survival rate for this group was 11.4% 
less than the mean rate). 
4. Severity of medical illness at the time of liver transplanta-
tion (3-year survival rate of the most critically ill was 24.3% 
less than for those with little stigmata of chronic liver disease). 
5. Primary diagnosis of malignant neoplasm (3-year survival 
rate for this group is 31.7% less than the mean rate). 
For graft survival. the risk factors were Similar, although the 
very young «1 year of age) recipients had the lowest graft 
survival (3-year graft survival rate is approximately 9% less 
than the mean rate). 
The corresponding biologic explanations for these risk fac-
tors are as follows: 
1. Concurrent medical conditions in the elderly. 
2. Greater severity of illness in those receiving more than 
one liver transplant. 
3. Higher incidence of hepatitis Band C as well as the 
presence of primary liver tumors in the Asian recipients com-
pared with other races. 
4. Higher risk in sicker patients, related to other organ 
system involvement such as respiratory or renal failure. 
In the pediatric population, a higher rate of technical com-
plications in liver transplantation accounts for the higher graft 
loss in this group. For several risk factors, the effect on both 
patient and graft survival appears to occur in the immediate 
post-transplant period, without a disproportionate loss after 
the first 3 months. 
Heart 
The 1- and 3-year patient survival rates after heart transplanta-
tion are 85.1 % and 76.2%. respectively; the corresponding 
graft survival rates are 84.5% and 74.2%. The similarity be-
tween patient and graft survival (",.Ites in heart transplantation 
is due to the limited retransplant at ions performed. For heart 
transplantation. the risk factors that adversely affect both pa-
tients and graft survival rates are as follows. listed in order of 
importance: 
1. Very young age « I year); both patient and graft survival 
r.Ites were 1-4"" less in this age group compared with the 
mean. 
2. Severity of medical illness at the time of heart trans-
plantation: recipiems with the most critical need for heart 
transplantation have a <)% worse .3-year outcome than those 
with minimum heart disease. 
3. Women have approximately 3"0 [() i'Yo worse patient and 
waft survival r.Ites than men. 
The corresponding biologic explanation for the first and 
third risk factors is the difficultv in obtaining heart grafts of 
appropriate size !t)r children and for women. The second 
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factor can be explained by the presence of concurrent medi-
cal illnesses in those who are criticallv in need of heart 
transplantation, as well as the use of bi~mechanical devices 
to maintain such patients until transplantation. 
Pancreas 
Pancreas transplantation has been used in the following three 
scenarios: 
• Pancreas alone, as treatment of type I juvenile-onset diabe-
tes mellitus, without overt renal failure 
• Pancreas combined with simultaneous kidney transplanta-
tion (SPK), for diabetic patients with renal failure 
• Pancreas after successful kidney transplantation (PAK) 
Overall, the current 1- and 3-year graft function rates for all 
pancreas transplants are 79.6% and 67.4%, respectively. In the 
national experience, patients undergoing SPK have fared the 
best, with 1- and 3-year graft survival rates of 80.8% and 
70.5%, compared with 63.5% and 40.2%, respectively, for pan-
creas alone; and 72.8% and 41.6%, respectively, for PAK. The 
biologic explanation for these differences lies in the difficulties 
in assessing pancreas rejection. In pancreas transplantation, 
elevation of the serum glucose is often a late sign of rejection, 
because only 10% of the islet mass may be present before 
overt diabetes mellitus reappears. Thus, reversal of rejection 
may not recover sufficient islet function to ensure long-term 
graft function. In SPK, the kidney has been used as a "win-
dow" to assess pancreas rejection. It has been assumed that 
treatment of kidney rejection will also treat rejection of the 
pancreas, which is occurring at the same time. In PAK, moni-
toring of pancreas rejection has been less successful; usually, 
the HLA types of the original kidney donor and of the pan-
creas donor are significantly different. 
The 1- and 3-year patient survival rates for pancreas trans-
plantation are 93.2% and 86.4%, respectively. For SPK, the 
corresponding survival rates are 93.2% and 86.4%. which are 
approximately 1.5% to 11.7% worse than for patients who 
receive kidney grafts alone. The higher morbidity and mortal-
ity rates associated with adding a pancreas transplant at the 
time of kidney transplantation are related to technical factors 
in pancreas grafting, such as a higher rate of infections after 
pancreas transplantation. 
Heart-Lung 
The number of heart-lung transplants has actually fallen, in 
part because of a shift of some candidates to just lung trans-
plantation. TIle patient survival rate is almost identical to the 
graft survival r.lte, because retransplantation is rare. The 1- and 
.3-year survival r.ltes are 74% and 51%, respectively. Because 
experience with this procedure is limited. detailed analysis of 
the risk factors is meaningless. 
Lung 
TIle patient survival r.lte after lung tr.lnsplantation is also 
similar to the gr.lft survival. owing to the limited experience 
with retr.lnsplantation. The 1- and .3-year patient survival r.ltes 
are 7"""(, and 58%. respectively; the corresponding graft sur-
vival r.ltes are 76°{, and 55%. respectively. Males tend to have 
poorer patient and graft survival rates (approximately 4% to 
"i% lower 1- and .3-year survival rates than for women). The 
biologic explanation tor this difference is not clear but may 
be related to differences in the indications for lung transplanta-
tion between men and women. 
7 $ t ,. r f 
Controversies 
One of the principal controversies about the meaning of the 
data cited in this discussion is the effect on national policies 
regarding organ allocation and possible restriction of trans-
plant services to selected groups of recipients. 19-21 Some re-
searchers have argued that the transplant community should 
restrict transplants to the patients who have the greatest 
likelihood of long-term survival, whereas others have viewed 
transplantation as a means to provide life-saving therapy to 
patients who have the most to gain (Le., the most critically ill). 
For example, the greatest net benefit of liver transplantation is 
for those patients whose outcomes without transplantation 
are poor. The net benefit is the difference in survival between 
those who receive transplants and those who do not. Data 
derived from UNOS have already shown that this difference 
(Le., net benefit) is greater for the sicker patients (on the 
order of 50",(, at 1 year) compared with the patients in whom 
transplantation was performed on the most elective basis (i.e., 
no difference in survival between those who received trans-
plants and those who remained on the waiting list for more 
than 2 years).22 
On Apri12, 1998, the U.S. Department of Health and Human 
Services (DHHS) issued final regulations regarding organ allo-
cation.2j These regulations require that policies that govern 
organ allocation must embody the following principles: 
1. Equity for patients awaiting organ transplantation as mea-
sured by waiting time. 
2. Access to transplant center data for patients. 
3. A "level playing field" through definition of standard 
listing and status criteria. 
4. Reaffirmation of the role of government oversight as 
public advocacy. 
5. Encouragement of patient participation in transplant is-
sues. 
These principles have been advanced by impartial panels. For 
example, in 1977, the American Medical Association Council 
on Ethical and Judicial Affairs l < affirmed that, "Organs should 
be considered a national, rather than a local or regional, 
resource. Geographical priorities in the allocation of organs 
should be prohibited: H In 1984, NOTA called for the fair and 
equitable national allocation of organs. TIle 1986 recommen-
dations by the U.S. Task Force on Organ Transplantation 
clearly stated the need to avoid using geography as the basis 
for organ distribution. Currently, these issues are being de-
bated within the transplant community, and UNOS is leading 
the opposition to adoption of these regulations; the likelihood 
that these regulations will be implemented is still unknown. 
However, in a 1998 editorial published in Tbe Lancet, Hortonl ' 
wrote, "UNOS would better serve the transplant community 
if it abandoned its stance and began working with DHHS to 
draw up allocation policies that are practical and fair," 
IMMUNOLOGIC ADVANCES 
Several new developments in the area of immunology and 
immunosuppression promise to affect organ transplantation 
in the near future. Chapter 178 has been devoted to the 
discussion of immunosuppressive agents; attention is given 
here to two areas that will influence our immunosuppressive 
management of recipients of solid-organ transplants. 
Chimerism 
Billingham and colleagues~D" l~ first associated tolerance to skin 
grafting with hematopoietic mixing or chimerism in freemar-
tin cattle and subsequently verified this finding by injecting 
4 
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viable allogeneic spleen cells into fetuses of the recipient 
strain. Ildstad and Sachsl • demonstrated the ability to duplicate 
mixed allogeneic lymphodendritic chimerism and subsequent 
tolerance by allogeneic bone marrow transplantation. The 
concept of natural microchimerism. which develops after 
solid-organ transplantation. was first suggested by clinical ob-
servations of acquisition of delayed-type hypersensitivity in 
recipients after successful kidney transplantation. '" This hy-
pothesis was documented years later. after technologic ad-
vances allowed for detection of small numbers of donor cells 
(outside the grafted organ) through the use ofimmunostaining 
or polymerase chain reactions (PCRs), in which donor deoxy-
ribonucleic acid is amplified.'o This pattern of migration of 
donor-derived cells after transplantation was subsequently 
found in experimental animal models" and in other human 
organ transplant models, such as liver and small-bowel trans-
plantation. 
The functionality of these cells was suggested in a study by 
Starzl and coworkers,'o in which an unexpected benefit of 
transplantation of the liver for type N glycogen storage disease 
resulted in reversal of the deposition of the insoluble defective 
polysaccharide. In this study, donor-derived cells were de-
tected in the heart and other tissues in two patients receiving 
liver transplants for type N glycogen storage disease. Similar 
findings were noted in a transplant recipient with a deficiency 
of the lysosomal enzyme B glucocerebrosidase. which causes 
type 1 Gaucher's disease. 
A more systematic survey of long-term survivors after liver 
transplantation was performed with the use of immunostain-
ing and polymerase chain reaction," Of a group of 22 surviv-
ing liver transplant recipients who had received their trans-
plants more than 10 years before being studied, all 
demonstrated systemic tissue microchimerism. The immuno-
logic privilege of the liver, its ability to induce systemic hypo-
responsiveness and to protect other organs from rejection, 
may lie in the relative abundance of migratory cells in the 
liver compared with other organs, such as the kidney and 
heart. If this hypothesis is correct. strategies can be developed 
to identify the cell type and the optimal source of these 
cells and then to enhance their migration. in an attempt to 
accentuate the immunomodulating effect of the cells on the 
reCipient immune response. 
The dfect of the migratory donor cells on the recipient 
immune response is not clear. It is likely that a number of 
factors determine the ultimate effect of these cells on allogrJft 
survival. First. if insufficient immunosuppression is given in 
the early phases after transplantation. these cells may be im-
munogenic and may accentuate the rejection process. Second. 
if the recipient is made immunoincompetent shortly before 
transplantation. either by cytoablation or by an imbalance in 
the number of immunocompetent donor cells given. a graft-
versus-host disease (GVHD) process may occur. in turn further 
suppressing the immunocompetence of the reCipient." Third. 
if an appropriate balance of immunosuppression is given, 
along with a sufficient number of migratory cells or their 
precursor stem cells. a phase in which the donor cells can 
migr.lte and take residence in the recipient foHows a phase in 
which peripheral anergy or coexistence may occur." Put into 
an immunologic perspective on tolerance (ranging from 
chronic infection to autoimmune diseases to transplantation), 
the outcome of immune effector functions after antigen expo-
sure depends on the dose. timing. route. and localization of 
the antigen." 
A number of observations have suggested these cells are of 
bone marrow origin. Donor-specific blood transfusions (DSTs) 
have been shown to enhance long-term graft survival in living 
donor kidnev transplants since the I 'X'Os. Cuchrum and asso-
ciates'" reported that DSTs improved l-,'ear graft survival by 
57% to 95%. Even in the cyclosporin era. Salvatierra and 
coworkers;7 reported a I-year graft survival of 93% in DST-
treated patients, compared with 82% in non-DST-treated pa-
tients. In addition, Reed and colleagues;· reported a benefit 
of DST in reducing both rejection and the need for steroids. 3M 
Protocols have been developed to infuse donor bone marrow 
at the time of solid-organ transplantation. Several groups, in-
cluding ours at the University of Pittsburgh, are currently 
using cadaveric bone marrow infusion, along with solid-organ 
transplantation from the same donor, in attempts to enhance 
the chimerism observed after solid-organ transplantation 
alone.,9-41 
University of Pittsburgh Experience 
At the University of Pittsburgh, since 1992, 226 primary allo-
graft recipients have received perioperative infusion of a sin-
gle dose of 300 to 500 million unmodified donor bone marrow 
cells per kg of body weight. The mean recipient and donor 
ages are 40 years and 29 years, respectively, and follow-up 
periods have ranged from 3 to 2023 days. 
Since April 1996, 39 organ recipients have been included 
in a protocol involving three daily sequential perioperative 
infusions of unmodified BM cells (200 million ceils/kg/day) 
from day 0 to 2 post-transplantation. The mean reCipient age 
in this group is 45 years, and the follow-up period has ranged 
from 4 to 790 days. Control subjects were those organ trans-
plant reCipients for whom bone marrow was not available (n 
= 131). Standard immunosuppression in this study consisted 
of tacrolimus and steroids. Mycophenolate mofetil (MMF) was 
used in 53 study patients and 17 control patients. In addition 
to serial monitoring of clinical parameters, peripheral blood 
from the recipients was screened for the presence of donor 
cell chimerism (by flow cytometry and PCR) and cellular 
immune responses (by mixed leukocyte reaction [MLR]). Infu-
sion of bone marrow cells was safe in all cases, and of the 55 
grafts (21 %) lost in study patients, none could be attributed 
exclusively to bone marrow infusion. Thirty-one (24%) of the 
control patients experienced loss of the allograft. A slightly 
higher incidence (77% versus 63%) of mild to moderate acute 
cellular rejection (ACR) was observed in the control group. 
Heart recipients demonstrated a statistically significant (P 
= .006 by Fisher's exact test) decrease in rejection episodes 
after BM infusion. Sixty-two per cent of study patients (as 
opposed to 18% of control patients) were free of rejection 
(grade 3A or higher) in the first 6 months after transplantation. 
Lung transplant recipients in the study group also showed a 
statistically lower incidence of obliterative bronchiolitis (3.8%) 
than the control group (31 %). 
Mild, easily reversible GVHD was observed in 1% (n = 2) 
of patients receiving single bone marrow infusions. Contrarily, 
fulminant GVHD was encountered in 1 of 39 recipients of 
multiple bone marrow infusions. This individual was a liver 
recipient, and in patients undergoing liver transplantation, we 
have reinstituted the single infusion strategy. In those patients 
evaluated at least 1 year after transplantation. a slightly higher 
incidence of steroid-free existence was noted in the bone 
marrow study group (53% versus 40%). This finding was asso-
ciated with a higher incidence of multHineage donor cell 
chimerism in study patients (95% of total study group) com· 
pared with the controls ('H% of total control group). In an 
evaluation using one-way MLR assays. donor-specific hyporeac-
tivity was witnessed in 57% of bone marrow-augmented liver. 
lung, and kidner reCipients compared with 44% of controls. 
Ricordi and colleagues" are conducting a similar study at 
the University of Miami. They have modified the infusion 
protocol to include the use of one or more donor bone 
marrow infusions during the earlv post-transplantation period. 
TItis group has suggested that multiple bone infusions are 
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associated with a lower incidence of acute rejection and 
higher levels of chimerism.42 In both of these trials, the con-
clusive clinical endpoint will be to determine the ability to 
wean bone marrow-infused and control transplant recipients 
from immunosuppression completely and to determine the 
incidence of the subsequent development of chronic rejec-
tion. 
Sirolimus (Rapamyein) 
Sirolimus (rapamycin) is a natural fermentation product (mac-
rolide antibiotic) with immunosuppressant properties that 
acts by inhibiting growth factor signal transductionY Its spe-
cific mechanism of action is the blockade of T and B cell 
responses to stimulating cytokines, thus preventing cell cycle 
progression in the phase of the cell cycle G, and subsequent 
cellular proliferation." llke cyclosporine, sirolimus is metabo-
lized in the cytochrome m4"D~ pathway and is a substrate for 
p-gl.ycoprotein countertransport. oj, Animal studies have shown 
that when combined with standard immunosuppressive ther-
apy, sirolimus allows for the reduction of individual drug 
dosages and leads to a remarkable decrease in the incidence 
of acute rejection. -i6 Although some studies found sirolimus 
levels to be consistently higher when the drug was adminis-
tered concomitantly with cyclosporine:' others found no 
pharmacokinetic interaction between the two agents.·7 Siroli-
mus prevented accelerated atherosclerosis in synergism with 
mycophenolic acid and reduced transplant vasculopathy.48.49 
This drug has also been said to have a putative beneficial role 
in the treatment and prevention of obliterative bronchiolitis 
when used in combination with other immunosuppressive 
agents in heart-lung transplantation.'o 
Toxicities associated with sirolimus include thrombocyto-
penia, leukopenia. increased cholesterol levels, elevated tri-
glyceride levels. anorexia, vomiting, diarrhea, diabetes melli-
tus, myocardial necrosis, and testicular atrophy.44. 'I-54 
Hypertension, nephrotoxicity, and hepatotoxicity have not 
been reported, "- 55 although potentiation of cyclosporine 
nephrotoxicity by sirolimus has been reported.'6 In vitro stud-
ies suggest that it may also have neurotoxic potentials." Siroli-
mus is now in phase III trials for renal transplant recipients; 
preliminary results indicate a decrease in acute rejection when 
sirolimus is used in combination with cyclosporine.58 
SDZ RAD (4().().(2-hydroxyethyl)-rapamycin), a rapamycin 
analog, also acts by inhibiting growth factor-driven cell prolif-
eration. Although it has less in vitro activity compared with 
sirolimus, SDZ RAD has similar immunosuppressive properties 
when given orally. '9.60 Clinical trials of this agent are currently 
under way. 
APPLICATIONS TO NEW ORGAN 
TRANSPLANTATION 
One way to assess the impact of a new immunosuppressive 
agent in transplantation is the ability to successfully transplant 
organs that were not considered feasible for transplantation 
with standard immunosuppression. This was certainly the situ-
ation when cyciosporine was introduced to liver transplanta-
tion. Chapters 182 to 184 deal with the topicS of lung, pan-
creas, and intestinal transplantation. respectively; a brief 
reference to the impact of tacrolimus in these organ trans-
plants is provided here. 
Intestinal Transplantation 
Success with intestinal transplantation using cyclosporine im-
munosuppression has been sporadic.""'" A growing experi-
ence of small-bowel transplantation. either alone or combined 
with other abdominal organs, with tacrolimus immunosup-
pression has been accumulated at the University of Pitts-
burgh,M-66 the University of Miami,67 the University of Ne-
braska,68 and the University Hospital in London, Ontario.69 At 
the University of Pittsburgh, small-bowel allografts have been 
transplanted alone (n = 37), along with livers (n = 50), or 
as part of multivisceral clusters (n = 17) using tacrolimus 
immunosuppression. Of the 98 patients who received these 
104 allografts, 48% were alive at a mean follow-up of 32 
months. The actuarial 1- and 5·year patient survival rates are 
72% and 48%, respectively. Graft function was satisfactory, 
with 91% of survivors being enteraily sustained and the other 
9% relying on supplemental parenteral nutrition. Rejection 
was common; 90% of the patients had at least one episode of 
rejection of the intestinal allograft. The high incidence of 
rejection may be altered by the addition of some of the newer 
immunosuppressive agents discussed in Chapter 178. 
Lung Transplantation 
Lung transplantation is a rapidly developing procedure that 
has been limited for technical, preservation, and immunologic 
reasons. A prospective, randomized trial of primary adult pul-
monary transplantation using tacrolimus immunosuppression 
was conducted at the University of Pittsburgh.70 Sixty-Six pa-
tients were randomly assigned to receive tacrolimus immuno-
suppression, and 66 patients to receive cyclosporine immuno-
suppression. Although 1- and 2·year patient survival rates were 
not statistically significantly different for the two regimens, 
there was a trend toward increased survival in the tacrolimus 
group. In addition, obliterative bronchiolitis developed in sig-
nificantly fewer patients in the tacrolimus group (22%) than 
in the cyciosporioe group (38%). 
In light of the lung allograft shortage, the utility of single 
lung transplantation rather than double lung transplantation 
for pulmonary hypertension has been established,71 although 
other indications, such as cystic fibrosis, preferentially require 
double lung transplantation.72 The organ shortage is reflected 
by a high incidence of deaths of patients on the waiting list. n 
Other approaches to increasing lung allograft availability are 
the development of living related donor bilateral lobar lung 
transplantation.7 •. -, The results reported from the University 
of Southern California revealed survival outcomes similar to 
those for tran.splantation from cadaveric donors, with no do-
nor mortality and a complication rate of 10%.74 
Islet Cell Transplantation 
For treatment of type I diabetes mellitus, islet cell transplanta-
tion would be preferable to whole pancreas transplantation. 
The morbidity and mortality associated with transplantation of 
the exocrine component of whole pancreas are well known. A 
number of investigators have developed automated systems 
of enzymatic and mechanical separation that have improved 
previous methods of islet cell isolation. 7"."" Application of this 
technique has proved to be applicable to clinical situations 
through infusion of purified islets into liver allografts, during 
combined liver-islet transplantation, and has resulted in long-
term islet function in selected cases of surgically induced 
diabetes mellitus. 7M The early experience with islet transplanta-
tion for treatment of juvenile-Qnset type I diabetes mellitus 
was less successful, although C.peptide secretion was almost 
uniformly observed.79 With improved isolation and immuno-
suppression. several cases of exogenous insulin freedom have 
been noted in patients undergoing combined kidney-islet cell 
transplantation."" The technical and immunologic factors are 
still being investigated.""·' However. its general clinical appli-
-->-- -~I -D-~-~--.... -,-,.---,,,--- ._", 
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cation awaits demonstration of improvements in long-term 
insulin freedom.·' 
ADVANCES AND INNOVATIONS IN 
SUPPORT SYSTEMS 
Extracorporeal Liver Assist Device 
Acute liver insufficiency can present as either fulminant he-
patic failure (FHF) or primary nonfunction (PNF) of liver 
allografts after liver transplantation. The clinical presentation 
is acute liver failure complicated by hepatic encephalopathy 
either in a previously healthy person (FHF) or after liver 
transplantation (PNF). Survival with either FHF or PNF is poor, 
particularly for patients suffering advanced encephalopathy 
with development of the hepatorenal syndrome, systemic lac-
tic acidosis, and severe coagulopathy. The morbidity and mor-
tality of FHF and PNF cannot be underestimated. The mortality 
rate of FHF is 60% to 95%; it is higher for FHF owing to virus 
or toxic exposure, and lower in patients with FHF owing to 
acetaminophen overdose. PNF occurs in up to 10% of patients 
after liver transplantation; contributing factors include donor 
instability and length of preservation times, although many 
cases of PNF have no predisposing factors. Mortality associ· 
ated with PNF is approximately 40% to 50%, even after retrans-
plantation. 
Management of both PNF and FHF is challenging and is 
aimed at prevention and treatment of complications, including 
infections, brain edema. hemodynamic instability, pulmonary 
and renal failure, acid-base disturbances, and coagulopathy. 
Orthotopic liver transplantation has increasingly been used 
for selected patients with FHE whereas orthotopic retrans-
plantation is the only procedure of choice in patients with 
PNE 
The concept of using mechanical devices to maintain pa-
tients with PNF or FHF until transplantation is an attractive 
one. Nevertheless. dialysis and charcoal hemoperfusion are 
not of proven benefit because (1) the multiple biochemical 
functions are not being replaced and (2) their use has not 
decreased the mortality in patients with FHF."'·"' Three pro-
posed systems have used a hybrid device containing metaboli-
cally active liver cells. 
Laboratory models have attempted to use primary hepato-
cyte cultures isolated from either animal or human livers: 
however. the inability to grow such cells in vitro has limited 
the practicality of this source of cells. Rozga and coworkers"" 
have used a liver support system consisting of plasma separa-
tion and perfusion through a charcoal filter and hollow-fiber 
cartridge with porcine hepatocytes attached to collagen-
coated dextran microcarrier beads, which are then placed into 
the extracapillary space of a hollow-fiber cartridge. Plasma 
is passed through the intracapillary space, and the porcine 
hepawcytes are separated from the plasma by the cartridge 
membrane. In a case report of a patient with FHF. total hepa-
tectomy with extracorporeal liver support was able to support 
the patient until orthotopic liver transplantation could suc-
cessfully be completed. In this case. intracranial pressures and 
serum ammonia were thought to be controlled with the use 
of the porcine hepatocyte-extmcorporeal liver assist device 
(ELAD) system. 
Watanabe and colleagues.·- in a phase I clinical trial, re-
ported encouraging results with the extracorporeal bioartifi-
cial liver. Their experience involved a total of 31 patients. Of 
18 patients with a diagnosis of FHF. 16 were maintained 
successfully until transplantation and one until recovery of 
native Ih'er function. Of three patients with PNF. all were 
successfullv maintained by the device until retmnsplantation. 
TIle remaining I () patients had a diagnosis of acute exacerba-
tion of chronic liver disease. Two of these were successfully 
maintained until recovery and transplantation. The other eight 
did not qualify for transplantation but were successfully 
treated with the bioartificial liver prior to their deaths. There 
were decreases in ammonia, bilirubin, and transaminase levels 
after treatment with the liver assist device. Coagulation param-
eters, including prothrombin time, did not improve_ There 
was an improvement (increase) in the ratio of branched chain 
amino acids to aromatic amino acids. 
The system described by Sielaff and colleagues88 at the 
University of Minnesota is similar in concept to the porcine 
hepatocyte- ELAD described above but uses a three-compart-
ment collagen gel entrapment of porcine hepatocytes in the 
lumens of hollow-fiber cartridges. Blood is passed through the 
extracapillary space, but the hepatocytes are protected from 
immune damage by the cartridge membrane.89 This system is 
being launched for phase I human trials. 
The third EI.AD system is based on the use of a subclone of 
HepG2 (HepG2/C3), a human hepatoblastoma cell line that 
expresses nearly normal levels of several central metabolic 
pathways and has the morphology and polarity characteristic 
of human hepatocytes."o HepG2/C3 can be grown in hollow-
fiber cartridges, with the intention of developing an extracor-
poreal liver assist device (C3-ELAD). Six human patients have 
been treated with C3-ELAD."' All of the patients had advanced 
encephalopathy at the start of therapy, and all were in an 
intensive care unit (ICU). The devices were used for between 
24 hours and 6 days. Improved clinical status, such as mental 
status, was noted in three of the six patients. One patient 
recovered completeiy from FHF. apparently as a result of C3-
ELAD. Two other patients first improved but died of non-liver-
related causes, one from sepsis 3 days after discontinuation of 
C3-ELAD therapy, and the other of brain death follOwing a 
period of hypotension not thOUght to be related to C3-ELAD 
therapy. The remaining three patients died, one during an 
unrelated diagnostic procedure, one owing to technical inabil-
ity to continue C3-ELAD therapy, and one because of advanced 
metabolic derangements related to liver failure_ 
A larger trial of this device was performed at the King's 
College Hospital. where a randomized trial of C3-ELAD was 
.:ompared with a control regimen. Although the patients re-
ceiving C3-ELAD therapy were noted to have a higher level of 
improvement in encephalopathy, survival was not different.o l 
Unfortunately, the unknown risk that immunosuppressed pa-
tients may be inoculated with tumor cells in the advent of a 
break in the hollow fibers, along with logistic difficulties, 
ended this trial. 
Hepatocytes obtained from livers considered unsuitable for 
transplantation have been isolated and determined to be via-
ble.93 All organs had been excluded primarily because of 
steatosis, although advanced donor age was a significant sec-
ondary consideration. These cells exhibited decreased length 
of viability in cell culture compared with hepatocytes ob-
tained from fresh surgical specimens. However, evidence of 
hepatocyte-specific function was shown by their ability to 
metabolize diazepam and lidocaine. Intrasplenic hepatocyte 
transplantation has been shown to improve the survival of 
laboratory animals with liver tailure and to lead to an improve-
ment in associated physiologic liver-based abnormalities."· The 
exact use of isolated hepatocytes and their human application 
is still to be determined. 
Strom and coworkerso, have used human hepatocytes to 
maintain patients with FHF until liver transplantation. Five 
hepatoq'te-treated patients were successfully maintained until 
liver transplantation. with improvement in cerebral perfusion 
and cardiac stability. In one published report, the use of 
allogeneic hepatoc"ytes partially reversed a liver disease due to 
an inborn error of metabolim. Cri!-:Ier-Najjar syndrome:'" 
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Some investigators have expressed concern for risk of dis-
ease transmission from the use of animal hepatocytes, al-
though human blood does not directly contact the animal 
hepatocytes. Swine herds can be maintained in specific patho-
gen-free facilities, and known pathogens, such as Brucella, 
can be screened out. The discovery of a pig endogenous 
retrovirus (PERV)97 that can be transmitted to human cells in 
culture, however, has raised safety concerns.98 Given the is-
sues related to organ shortage and the need for support of 
patients with acutely failing livers, cautious exploration of 
bioartificial liver support devices appears warranted, in order 
to identify those areas that will require further study. Techno-
logic advances and better screening tools are likely to identify 
donor livers that may harbor latent infections. 
Bloartificial Pancreas 
Unlike totally artificial pancreas devices (in which exogenous 
insulin is placed into a pump and delivered via a glucose 
sensor),99 bioartificial pancreas devices rely on the presence 
of the natural glucose homeostasis mechanisms of the beta 
cell. Biohybrid artificial pancreatic devices have been made in 
which cultured cell lines derived from pancreatic islet cells 
were placed within three-layered encapsulating microbeads, 
were inserted subcutaneously, and functioned in a rat 
model. 100 Bioartificial constructs with transformed cells have 
also been suggested as an alternative, given the scarcity of 
islets cells. 10' Encapsulated xenografted islets were found to 
control carbohydrate metabolism in pregnant diabetic animals 
and may eliminate the higher incidence of fetal malformations 
observed in diabetic pregnancies. 102 
Artificial Heart Assist Devices 
Owing to the success of heart transplantation. artificial heart 
assist devices have been used primarily to maintain patient 
survival until the time of transplantation. Power supplies and 
the complications arising from the interaction of a foreign 
surface with the blood remain major issues still to be resolved. 
Animal studies have employed electromechanical artificial 
hearts of reduced dimensions driven by transcutaneous energy 
systems that may evolve into devices of permanent implanta-
tion for humans. Several systems (Novacor. Thoratec. Heart-
Mate) have been tested in humans, primarily as bridges to 
heart transplantation. IO.\-I'" Although these devices are effec-
tive in restoring cardiac output and reversing the sequelae of 
cardiogenic shock, major complications have included 
drive line infection and thromboembolic strokes. 
The U.S. Food and Drug Administration (FDA) granted ap-
proval for the use of a Ventricular Assist Device (VAD) System 
in patients recovering from open-heart surgery. The device, 
manufactured by Thoratec Laboratories of Pleasanton, Calif., 
has already been approved for use as a bridge prior to cardiac 
transplantation. This makes the VAD System the only device 
c1inicallv available in the United States for the treattnent of 
patients' on a short-term or long-tertn basis. It remains to 
be determined whether these devices will be cost effective 
compared with heart transplantation and prolonged medical 
therapy. 11K, 
EXPANSION OF THE DONOR POOL 
Non-Heart-Beating Donors 
Before the acceptance of brain death. the heart function of 
any organ donor was required to have ceased before the 
organs could be procured for transplantation. In some coun-
tries where brain death legislation has not been passed. non-
heart-beating donors (NHBDs) represent the principal source 
of organs for transplantation. Four distinct populations of 
NHBDs have been identified and are classified as follows by 
Kootstra 107: 
1. Uncontrolled cardiopulmonary arrest-dead on arrival. 
2. Uncontrolled cardiopulmonary arrest-declared dead fol-
lowing unsuccessful cardiac resuscitation in hospital. 
3. Cardiac arrest under conditions of removal from life 
support, without fulfillment of criteria for brain death. 
4. Cardiac arrest in a brain-dead patient. 
The first situation is unlikely to generate usable organs, 
because the warm ischemic time would be unknown. In 
the second scenario, reasonable expectation of organ survival 
would require either immediate procurement of organs or 
infusion of preservation solution into the individual pro-
nounced dead in a setting where family consent may not be 
available. A pilot study of such a procedure has been initiated 
by the Regional Organ Bank of Illinois; it is based on in 
situ perfusion of the abdominal aorta with a double-balloon 
catheter. '08 The fourth situation does not require any consider-
ation except expedient procurement of organs, because con-
sent for organ donation has generally been obtained. 
The third situation is that of using organs from a patient 
who does not yet fulfill brain death criteria but for whom a 
desire has been expressed, by either the patient or the family, 
for the removal of life support so that the patient may become 
an organ donor after the declaration of death. Such a protocol 
has been developed by the University of Pittsburgh Medical 
Center and the Center for Organ Recovery and Education, 
which is the organ procurement organization associated with 
the geographic area of Pittsburgh. This protocol was devel-
oped in response to a perception that some families wished 
to have the right to tertninate life support and to donate 
organs. After lengthy review, a protocol was implemented 
in 1992. 
The details of this protocol are worth discussing, because 
they may fortn a foundation for further developments in this 
field. Th.e interest in using NHBDs is indicated by the develop-
ment of protocols among organ procurement organizations 
(OPOs) in the United States and the potential controversies 
they generate. '09. 110 In 1997, in Cleveland, Ohio, the lack of 
clarity in one set of protocols for organ procurement gener-
ated controversy that resulted in their withdrawal by the OPO 
concerned. '" In addition, the lack of unifOrtn criteria and 
policies for NHBDs was the topic of the 1997 hearings con-
ducted by the Institute of Medicine (10M) and of its subse-
quent report. III 1bis issue is particularly important given the 
growing utilization of NHBDs in the United States. According 
to the 1997 Annual UNOS Report, NHBDs accounted for 1 % 
of all cadaveric donors from 1994 to 1996 (162 of 15,874).'· 
A number of principles have been suggested for a NHBD 
protocol to ensure that patients, health care providers, and 
potential recipients are safeguarded.' Il The most important 
recommendations are summarized here: 
1. Written, locally approved NHBD protocols. 
2. Public openness of NHBD protocols. 
3. Case-by<:ase deCisions on anticoagulants and vasodila-
tors. 
4. Family consent for premortem cannulation. 
5. Safeguards against conflict of interest-separate times 
and personnel for important decisions. 
6. Detertnination of death in controlled NHBDs as cessation 
of cardiopulmonary function for at least 5 minutes as indicated 
by electrocardiographic and arterial pressure monitoring. 
7. Family options (e.g., attendance at life support with-
drawal) and financial protection. 
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A report by Yokoyama and coworkers II 3 from Japan revealed 
that the 1-year graft survival rates of 110 kidney allografts 
taken from NHBDs were similar to those reported for organs 
from brain-dead NHBDs. At the University of Pittsburgh, simi-
lar results have been obtained for both kidney and liver allo-
grafts taken from NHBDs.'" Cho and associates '" compared 
the early function and survival of more than 200 kidneys from 
NHBDs with those of more than 8700 control grafts from 
donors with heart beats. Graft survival rate at 1 year was 83% 
for the former and 86% for the latter: 48% of recipients of 
NHBD kidneys required dialysis within the first week after 
transplant, compared with 22% of the control group. Despite 
the delayed function, however, survival rates were high for 
both groups. Primary failure rate was 4% for NHBD kidneys 
and 1 % for kidneys from donors with heart beats. Among 
NHBD kidneys, grafts from donors who died as a result of 
trauma had a statistically significant better 1-year survival than 
grafts from donors who had died of other causes. lIS 
Xenotransplantation 
To understand the trends in the development of xenotrans-
plantation, we must realize that potential donors for cross-
species transplantation into humans can be separated into 
two groups. Donors can be considered either discordant or 
concordant. A discordant combination is characterized by the 
presence of a preformed antibody in the recipient, usually at 
high titers, that reacts and causes hyperacute rejection of the 
donor organ. Concordant combinations are generally charac-
terized by low or nonexistent antibodies, so that the resultant 
rejection process resembles that of an allograft.116 For exam-
ple, transplants from primates into humans are usually concor-
dant, whereas cross-species transplant from a pig into a human 
would be discordant. 
10 animal studies, the organ rejection in concordant combi-
nations usually occurs in a different time frame from that in 
discordant combinations. Livers and hearts from an untreated 
discordant combination are rejected by antibodies within 
minutes to hours after revascuIarization. These organs would 
be rejected days to weeks after transplantation in an untreated 
concordant combination. We also realize that liver grafts are 
less susceptible to antibody-mediated injury than kidney or 
heart grafts. This difference has been used in some attempts 
at clinical xenotransplantation, with the expectation that liver 
xenografts may be more likely to succeed than other types of 
xenografts. 
If one follows this train of thought, liver xenografts may be 
envisioned in three different clinical settings. The first would 
be to use liver xenografts as a temporary support, either until 
the liver recovers from injury or as a "bridge" to transplanta-
tion. These organs could be perfused outside the recipient, in 
an ex vivo manner. Such an approach was reported in a 
number of early experiences in the 1960s and again by the 
Johns Hopkins University and Duke University groUpS.1I7 10 
the second situation, heterotopic liver xenotransplantation 
might be envisioned as a bridging method until an appropriate 
human liver is found. Finally, permanent orthotopic replace-
ment of a diseased liver with a liver xenograft can be consid-
ered as a definitive procedure that may potentially expand the 
donor pool. 
Several general therapeutic considerations may be taken 
into account in xenotransplantation. The first deals directly 
with the selection of an appropriate donor species. if an initial 
high titer of cytotoxic antibodies is noted in the recipient, 
these antibodies must be depleted. The depletion can be 
achieved either specifically, by immunoabsorption, or nonspe-
cifically, by removal of plasma immunoglobulins. Once a suit-
able environment is created, in which the likelihood of hyper-
acute rejection is reduced, one must sustain a low titer of 
cytotoxic xenoantibody levels in the early post-transplant pe-
riod, usually by pharmacologic methods. The second consider-
ation is to minimize the inflammatory cascades that amplify 
the immune system. Specifically, complement activation leads 
to a number of inflammatory mediators that are difficult to 
control. Agents that can interfere with this cascade and the 
subsequent inflammatory mediators must be developed. fi-
nally, sustained suppression of cell-mediated rejection is im-
portant to minimize the long-term damage to the xenograft 
that may occur via lymphocyte-derived cytokines. 
Other considerations regarding the success of xenotrans-
plants depend on the compatibility of proteins between the 
donor and recipient speciesl18 as well as potential for infec-
tious diseases.' '9 These are areas of immense interest to physi-
cians studying xenotransplantation. Although three liver xeno-
transplantations have failed, the longest remaining viable for 
72 days, important facts about the pathology, immunology, 
compatibility, and physiology were obtained and will aid in 
future attempts. I 20-122 Although the baboon-ta-human xeno-
transplants were encouraging, the limiting factors in the pur-
suit of concordant xenotransplantation are "humanization of 
primates; limited availability, donor size incongruity, and the 
theoretical risk of transmitting infectious agents. These con-
cerns have prompted a quest to seek aIternative sources of 
animals for clinical xenotransplantation. 
Pigs are available in sufficient quantities, are similar in anat-
omy and physiology to humans, and can be bred under condi-
tions where they can be genetically modified. These factors 
have prompted the consideration of this species as a source 
for clinical xenotransplantation, but hyperacute rejection me-
diated by naturally occurring antibodies (also called "pre-
formed xenoantibodies") presents a formidable challenge. Be-
cause of the difficulty in controlling hyperacute rejection, 
novel approaches are required to overcome this barrier to 
successful discordant xenotransplantation. 
One strategy that has been utilized is the removal of pre-
formed antibodies from the recipient's blood prior to trans-
plantation (a process known as plasmapheresis). Although 
this approach has been utilized in ABO blood type-
incompatible human-to-human transplants with some success, 
its application in xenotransplantation has been limited, owing 
to the rapidity with which the preformed xenoantibodies are 
produced, resulting in rapid restoration of xenoantibody levels 
and leading to hyperacute rejection. 122 Strategies to eliminate 
xenoantibody production have not been successful, and alter-
native approaches must therefore be taken. Preformed 
xenoantibodies playa vital role in mediating hyperacute rejec-
tion, but they are not the effector molecules responsible for 
the observed damage in discordant xenografts. Antibody bind-
ing to the xenograft results in activation of another family of 
proteins, complement, which is normally present in circulat-
ing blood. These proteins exist in an inactive form but are 
activated when antibody binds to the target cells, resulting in 
damage to the cell. Normally, this process is self-limited by a 
process of inactivation by a group of cell surface-associated 
proteins called complement Inhibitory proteins. Why, then, 
is activated complement in the discordant xenograft not ren-
dered inert by these complement inhibitory proteins? 
Complement inhibitory proteins can interact only with 
complement of the same species and not with that of different 
species (homologous species restriction); this limitation may 
play an important role in liver xenotransplantation, because 
the liver is the primary source of complement synthesis. m 
Thus, following pig-to-human xenotransplantation, activated 
human complement will not be inactivated by the comple-
ment inhibitory proteins found on pig cells. One unique ap-
proach to this problem entails expressing human complement 
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inhibitory proteins on pig cells; this has been achieved by 
generating genetically modified pigs that carry the genes for 
human complement inhibitory proteins. Organs obtained from 
these transgenic pigs enjoy prolonged survival when trans-
planted across discordant barriers. suggesting that the human 
complement inhibitory proteins inserted genetically into the 
pig organ can overcome hyperacute rejection. 1Z4-1Z6 In these 
recipients. however. xenograft rejection still occurs by less 
understood mechanisms. including antibody-directed cell-me-
diated cytotoxicity. This finding suggests that additional ap-
proaches must be employed to overcome the immunologic 
barrier of xenotransplantation. IZ7 
SUMMARY 
The field of transplantation bas grown tremendously In tbe 
45 years since tbe first successful buman organ transplant. 
A better understanding of tbe Immune mecbanisms tbat 
cause graft damage, as weU as new immunosuppressive 
agents, bas belped put transplantation in a tberapeutic 
realm. Unfortunately, witb tbe success of transplantation, 
tbe scarcity of donor organs remains one of tbe principal 
limitations for broader applications. More tban 7000 pa-
tients die every year wblle waiting for an organ; in tbe 
United States. for every individual wbo receives a transplant, 
three otbers are added to tbe waiting list. Efforts are con-
stantly made to expand tbe donor pool, eitber by tbe use of 
donors who do not fUlfiU the criteria once applied to living 
donors or by xenotransplantation. Each of the next ad-
vances in the expansion of tbe donor pool is likely to gener-
ate controversy and wiU require careful scientific approacbes 
to ensure the safety of the recipients. Other developments in 
tbe areas of bloartificial-totaUy artificial support devices 
and xenotransplantation-are of significant interest, be-
cause their successful development wiU address the organ 
shortage problem. 
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